Monitor for initiation of a Phase 1 study of EQ504, which the forward-looking statements reference as an expected milestone. No near-term catalyst from this preclinical data alone.
Price Chart
Executive Summary
Equillium announced new preclinical data for its EQ504 program, a selective AhR modulator for ulcerative colitis, to be presented at the 7th International AHR Conference. The data characterize EQ504's multi-modal activity including epithelial barrier repair and immune modulation, but remain preclinical with no clinical data or regulatory milestones. This is a routine scientific update with no material financial impact.
Key Facts
- New preclinical data for EQ504 to be presented at the 7th International AHR Conference (Sept 29 - Oct 2, 2026) in Porto, Portugal
- Two poster presentations cover EQ504's effects on epithelial barrier repair and immune balance via AhR modulation
- EQ504 is an investigational, potent, selective AhR modulator in preclinical development for ulcerative colitis and potentially other GI/inflammatory lung diseases
- No clinical data, regulatory milestones, or financial figures disclosed in the release
Financial Impact
No financial impact — preclinical data presentation with no revenue, cost, or funding implications disclosed
Risk Factors
- EQ504 remains in preclinical stage with no clinical safety/efficacy data; risk of failure in future trials
- Equillium's forward-looking statements note going concern risk and need for additional financing to advance EQ504
- Preclinical data may not translate to clinical benefit in humans
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3371324 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $1.29 | awaiting T+60 | — | $1.36 (−5.43%) |
Oct 26, 2026 1d ago | Press Release | $1.25 | awaiting T+60 | — | $1.36 (+8.80%) |
Oct 5, 2026 22d ago | 8-K | $1.42 | awaiting T+60 | — | $1.36 (−4.23%) |
Oct 5, 2026 22d ago | Press Release | $1.42 | awaiting T+60 | — | $1.36 (−4.23%) |
Sep 29, 2026 28d ago | Press Release | $1.63 | awaiting T+60 | — | $1.36 (−16.31%) |
Jun 11, 2026 19w ago | Institutional Cluster | $2.81 $2.21 | ▼ −21.35% | ▼ −25.75% | $1.36 (−51.60%) |
Jun 5, 2026 20w ago | Insider Cluster | $2.77 $2.21 | ▲ +20.40% | ▲ +23.45% | $1.36 (+50.90%) |
May 29, 2026 21w ago | Insider Cluster | $3.08 $2.18 | ▼ −29.22% | ▼ −30.45% | $1.36 (−55.84%) |
May 20, 2026 22w ago | Press Release | $2.21 | awaiting T+60 | — | $1.36 (−38.46%) |
Apr 17, 2026 27w ago | EFFECT | $2.05 $2.76 | ▲ +34.63% | ▲ +28.49% | $1.36 (−33.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers